Gene-environment interactions in the development of chronic obstructive pulmonary disease

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 5, 2006, Pages 323-328

  Caramori, Gaetano ^a   Adcock, Ian ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Antiprotease; Chronic obstructive pulmonary disease; Gene environment interaction; Inflammation; Protease; Smoking

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIOXIDANT; BIOLOGICAL MARKER; ENZYME; PROTEINASE; PROTEINASE INHIBITOR; XENOBIOTIC AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENE INTERACTION; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; LUNG EMPHYSEMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL AIRWAY DISEASE; SMOKING;

DISEASE SUSCEPTIBILITY; ENVIRONMENT; GENES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 33748523035     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000244791.18486.f7     Document Type: Review

References (33)

1. Caramori G, Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 2003; 16:247-277.
2. Pauwels RA, Buist AS, Ma P, et al. and the GOLD Scientific Committee. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. NIH Publication no. 2701:1-100. Bethesda, Maryland: National Heart, Lung and Blood Institute. 2005. http://goldcopd.com/download. asp?intId=231 (Accessed 10 July 2006).
3. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22:672-688.
4. Mallia P, Johnston SL. Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2005; 2:361-366.
5. Silverman EK. Progress in chronic obstructive pulmonary disease genetics. Proc Am Thorac Soc 2006; 3:405-408. An excellent review covering study design as well as much of the information regarding the early papers examining gene-environment interactions.
6. Adcock IM, Ford P, Barnes PJ, Ito K. Epigenetics and airways disease. Respir Res 2006; 7:21 [Epub ahead of print].
7. Dahl M, Hersh CP, Ly NP, et al. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J 2005; 26:67-76. A meta-analysis of α1-antitrypsin polymorphisms in COPD.
8. Ito I, Nagai S, Handa T, Muro S, et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172:1378-1382. This paper demonstrates that MMP9 is associated with a specific subtype of COPD - upper-lung emphysema - and emphasizes the need to phenotype patients carefully.
9. Kelleher CM, Silverman EK, Broekelmann T, et al. A functional mutation in the terminal exon of elastin in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2005; 33:355-362. This is the first paper to describe the use of rare-variant analysis techniques in COPD, making use of the fact that patients with cutis laxa, a rare genetic syndrome related to improper elastic-fibre processing, often get emphysema in childhood.
10. Hegab AE, Sakamoto T, Uchida Y, et al. Association analysis of tissue inhibitor of metalloproteinase2 gene polymorphisms with COPD in Egyptians. Respir Med 2005; 99:107-110. Paper demonstrates that TIMPs as well as MMPs may be important in the genetics of COPD.
11. DeMeo D, Mariani TJ, Lange C, et al. The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am J Hum Genet 2006; 178:253-264. The first use of the strategy of selecting candidate genes within a linkage region via gene-expression patterns in relevant tissues.
12. Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3:440-443.
13. Matheson MC, Ellis JA, Raven J, et al. Association of IL8, CXCR2 and TNF-alpha polymorphisms and airway disease. J Hum Genet 2006; 51:196-203. This paper indicates that CXCR2 rather than CXCR8 polymorphisms may be important for neutrophil recruitment in COPD.
14. Stemmler S, Arinir U, Klein W, et al. Association of interleukin-8 receptor alpha polymorphisms with chronic obstructive pulmonary disease and asthma. Genes Immun 2005; 6:225-230. This paper indicates that CXCR2 rather than CXCR8 polymorphisms may be important for neutrophil recruitment in COPD.
15. Arinir U, Klein W, Rohde G, et al. Polymorphisms in the interleukin-8 gene in patients with chronic obstructive pulmonary disease. Electrophoresis 2005; 26:2888-2891.
16. Hegab AE, Sakamoto T, Saitoh W, et al. Polymorphisms of TNFalpha, IL1beta, and IL1RN genes in chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2005; 329:1246-1252. This paper demonstrates that specific interleukin-1β haplotypes were associated with different ethnic groups.
17. Chierakul N, Wongwisutikul P, Vejbaesya S, Chotvilaiwan K. Tumor necrosis factor-alpha gene promoter polymorphism is not associated with smoking-related COPD in Thailand. Respirology 2005; 10:36-39.
18. Seifart C, Dempfle A, Plagens A, et al. TNFa-, TNFb-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 2005; 65:93-100. This paper suggests that increased inflammation in COPD may relate to polymorphisms in the anti-inflammatory gene interleukin-10.
19. Jiang L, He B, Zhao MW, et al. Association of gene polymorphisms of tumour necrosis factor-alpha and interleukin-13 with chronic obstructive pulmonary disease in Han nationality in Beijing. Chin Med J (Engl) 2005;118:541-547. This paper shows an association of TNFa and interleukin-13 polymorphisms with increased risk of COPD in smokers rather than with COPD itself.
20. Asada M, Yamaya M, Ebihara S, et al. Interleukin-1β gene polymorphisms associated with COPD. Chest 2005; 128:1072-1073. This paper demonstrates an association of interleukin-1β polymorphisms with COPD in Japanese subjects.
21. Hoffjan S, Stemmler S, Parwez Q, et al. Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet 2005; 6:34.
22. Cipriano C, Caruso C, Lio D, et al. The -308G/A polymorphism of TNF-alpha influences immunological parameters in old subjects affected by infectious diseases. Int J Immunogenet 2005; 32:13-18.
23. Celedon JC, Lange C, Raby BA, et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004; 13:1649-1656.
24. Su ZG, Wen FQ, Feng YL, et al. Transforming growth factor-beta1 gene polymorphisms associated with chronic obstructive pulmonary disease in Chinese population. Acta Pharmacol Sin 2005; 26:714-720.
25. Young RP, Hopkins R, Black PN, et al. Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax 2006; 61:394-399. This paper shows that genetic variants of SOD and catalase are associated with impaired lung function in COPD.
26. Juul K, Tybjaerg-Hansen A, Marklund S, et al. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:858-864. Using both cross-sectional and prospective methods this paper shows that the G allele and CG/GG phenotype of the 213 SOD3 polymorphism is associated with increased antioxidant capacity and protects against the development of COPD.
27. Park JY, Chen L, Wadhwa N, Tockman MS. Polymorphisms for microsomal epoxide hydrolase and genetic susceptibility to COPD. Int J Mol Med 2005; 15:443-448. This paper demonstrates that xenobiotic enzymes may modify the risk for the development of COPD.
28. Rodriguez F, de la Roza C, Jardi R, et al. Glutathione S-transferase P1 and lung function in patients with alpha1-antitrypsin deficiency and COPD. Chest 2005; 127:1537-1543. The frequency of the glutathione S-transferase P1 105V polymorphism was identical in COPD patients and the general population but the frequency was significantly increased in patients with α1-antitrypsin deficiency and was associated with reduced lung function, emphasizing gene-environment effects.
29. Anderson GP, Bozinovski S. Acquired somatic mutations in the molecular pathogenesis of COPD. Trends in Pharmacol Sci 2003; 24:71-76.
30. Lee YL, Chen W, Tsai WK, et al. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. J Lab Clin Med 2006; 147:228-233. The frequencies of genotypes of p53 codon 72 and p21CIP codon 31 were significantly different between the COPD and the control groups.
31. Hersh CP, DeMeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 2005; 33:71-78. This paper demonstrates the difficulty in replicating gene associations in patients with COPD and discusses many of the reasons for this and the controls necessary to improve replication rates.
32. Hersh CP, DeMeo DL, Lazarus R, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 173:977-984. This study highlights the importance of not only the need to examine multiple SNPs or haplotypes in each subject but to compare these with a range of biomarkers for the disease.
33. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005; 6:95-108. This paper reviews the huge potential and complications of performing genome-wide studies on complex diseases such as COPD.